Nine-month interim report (Q3) 2025 (unaudited)

About this update from Alk-abello A/s Class B

ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded. Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. G rowth rates are stated in local currencies (l.c.), unless otherwise indicated. Financial highlights Allergy+ strategy highlights 2025 full-year outlook Today, ALK upgraded the full-year outlook based on the performance in Q3 and the outlook for the remainder of the year. The changes mainly reflect the current business momentum in Europe: Commenting on the Q3 results, CEO Peter Halling said: “In Q3, we saw a continued positive momentum in the execution of key strategic growth initiatives, most notably the roll-out of respiratory tablets for young children, which are ahead of plan. While still at an early stage, the children indications are increasingly contributing to growth, and we look forward to making these important treatments available to many more patients in the years ahead. This reinforces our confidence in our ability to deliver sustained, profitable growth by reaching more patients with evidence-based allergy and anaphylaxis solutions." Hørsholm, 12 November 2025 ALK-Abelló A/S For further information, contact: Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 ALK is hosting a conference call for analysts and investors at 1.30 p.m. (CET) on 13 November 2025 at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net where the relevant presentation will be available shortly before the call begins. To register for the conference call, please use this link and follow the registration instructions. You will receive an email from [email protected] with dial-in details, including a passcode and a pin code. Please make sure to whitelist [email protected] and/or check your spam filter. We advise you to register well in advance and to call in before 1.25 p.m. (CET). Attachment

View stock analysis, news, and events for Alk-abello A/s Class B